Email

Print

Tweet

Digg!

Del.icio.us

Critical step toward U.S.. marketing launch of MuGard

DALLAS, TX, December 15, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today announced the appointment of Frank Jacobucci to the position of Vice President, Sales and Marketing.  Mr. Jacobucci will be primarily responsible for the Company’s marketing launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.  Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.  Mr. Jacobucci has significant experience launching pharmaceutical products, with a particular expertise in oral mucositis and related oncology supportive care therapies and also has developed significant experience with MuGard.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Health care professional and patient feedback very positive

DALLAS, TX, December 3, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access’ partner, SpePharm, in six European countries, including the UK, Germany, Italy, Norway, Greece and Sweden. Access is conducting pre-marketing activities, including ramping of commercial production, with the goal of a commercial launch in 1H 2010 in the US. MuGard was granted the CE mark certification in Europe in late 2008 with the labeling “prevention and management of the lesions and symptoms of oral mucositis.”  Key findings and feedback from SpePharm’s ongoing commercial launch and patient assessment project include:
Read more »